ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.290
+0.060 (4.88%)
Apr 23, 2025, 4:00 PM EDT - Market closed
ADC Therapeutics Stock Forecast
ADCT's stock price has decreased by -72.44% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADC Therapeutics stock have an average target of 7.75, with a low estimate of 7.00 and a high estimate of 8.00. The average target predicts an increase of 500.78% from the current stock price of 1.29.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADC Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Hold | 1 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Guggenheim | Guggenheim | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +442.64% | Mar 31, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +520.16% | Mar 31, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Mar 7, 2025 |
Stephens & Co. | Stephens & Co. | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +520.16% | Feb 24, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +520.16% | Jan 6, 2025 |
Financial Forecast
Revenue This Year
75.67M
from 70.84M
Increased by 6.82%
Revenue Next Year
89.71M
from 75.67M
Increased by 18.56%
EPS This Year
-1.53
from -1.62
EPS Next Year
-1.23
from -1.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 84.5M | 122.4M | 187.6M | ||
Avg | 75.7M | 89.7M | 152.2M | ||
Low | 68.2M | 71.1M | 127.6M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 19.3% | 61.8% | 109.1% | ||
Avg | 6.8% | 18.6% | 69.7% | ||
Low | -3.7% | -6.0% | 42.2% |
EPS Forecast
EPS | 2025 | 2026 |
---|---|---|
High | -1.21 | -0.90 |
Avg | -1.53 | -1.23 |
Low | -1.82 | -1.67 |
EPS Growth
EPS Growth | 2025 | 2026 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.